Jerusalem, March 31, 2026 - Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ®  today announced that an abstract presenting results of two clinical trials in Jerusalem in patients with pancreatic cancer has been accepted for an oral presentation at Digestive Disease Week (DDW) 2026, the world’s premier international gastroenterology conference . This marks the first time that clinical result

Jerusalem, March 16, 2026 - Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ®  today announced that CFO Raphi Levy will present at the Sidoti Virtual Small Cap Conference taking place on March 18 - 19, 2026. Event: Sidoti Virtual Small Cap Conference Format: Company Presentation Date: March 18, 2026 Time: 10:00 – 10:30AM ET Location: Virtual Mr. Levy will be available for 1x1 investor meeti

Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update

Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Certain Head and Neck Cancers

Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Showcasing Immune-Preservation and High Disease Control

Alpha Tau announced the submission of the first module of its pre-market approval (PMA) application FDA

- The overview presentation will review some of the Company’s recent achievements as well as the outlook for upcoming data milestones - JERUSALEM, December 18 th , 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced that CEO Uzi Sofer and CFO Raphi Levy   will present a corporate overview and update at the J.P. Morgan 2026 Healthcare Conference on Th

- First patient in the world treated with Alpha DaRT ®  in the brain – - According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cancers, with an estimated average survival rate of only 8 months – - This pilot study is a key part of Alpha Tau’s broader strategy to bring Alpha DaRT to cancer patients with some of the highest unmet needs - Jerusalem, December 9, 2025 - Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW)

Pancreatic cancer multi-center clinical trial in U.S. is underway; patient recruitment expected to be completed by the end of Q1 2026 JERUSALEM, December 4, 2025 -- Alpha Tau Medical Ltd.  ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , announced today that two abstracts have been accepted to the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, to be held